Chakroborty Shreaya, Kim Joyce, Schneider Corinne, West Anthony R, Stutzmann Grace E
Department of Neuroscience, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064.
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15216, and.
J Neurosci. 2015 Apr 29;35(17):6893-902. doi: 10.1523/JNEUROSCI.4002-14.2015.
Synaptic plasticity deficits are increasingly recognized as causing the memory impairments which define Alzheimer's disease (AD). In AD mouse models, evidence of abnormal synaptic function is present before the onset of cognitive deficits, and presents as increased synaptic depression revealed only when synaptic homeostasis is challenged, such as with suppression of ryanodine receptor (RyR)-evoked calcium signaling. Otherwise, at early disease stages, the synaptic physiology phenotype appears normal. This suggests compensatory mechanisms are recruited to maintain a functionally normal net output of the hippocampal circuit. A candidate calcium-regulated synaptic modulator is nitric oxide (NO), which acts presynaptically to boost vesicle release and glutamatergic transmission. Here we tested whether there is a feedforward cycle between the increased RyR calcium release seen in presymptomatic AD mice and aberrant NO signaling which augments synaptic plasticity. Using a combination of electrophysiological approaches, two-photon calcium imaging, and protein biochemistry in hippocampal tissue from presymptomatic 3xTg-AD and NonTg mice, we show that blocking NO synthesis results in markedly augmented synaptic depression mediated through presynaptic mechanisms in 3xTg-AD mice. Additionally, blocking NO reduces the augmented synaptically evoked dendritic calcium release mediated by enhanced RyR calcium release. This is accompanied by increased nNOS levels in the AD mice and is reversed upon normalization of RyR-evoked calcium release with chronic dantrolene treatment. Thus, recruitment of NO is serving a compensatory role to boost synaptic transmission and plasticity during early AD stages. However, NO's dual role in neuroprotection and neurodegeneration may convert to maladaptive functions as the disease progresses.
突触可塑性缺陷越来越被认为是导致阿尔茨海默病(AD)所特有的记忆障碍的原因。在AD小鼠模型中,异常突触功能的证据在认知缺陷出现之前就已存在,表现为仅在突触稳态受到挑战时(如抑制兰尼碱受体(RyR)诱发的钙信号传导时)才显现出的突触抑制增强。否则,在疾病早期阶段,突触生理表型看起来是正常的。这表明机体启动了代偿机制来维持海马回路功能上正常的净输出。一种候选的钙调节突触调节剂是一氧化氮(NO),它在突触前起作用以促进囊泡释放和谷氨酸能传递。在这里,我们测试了在症状前AD小鼠中观察到的RyR钙释放增加与异常的NO信号传导之间是否存在前馈循环,而异常的NO信号传导会增强突触可塑性。通过结合使用电生理方法、双光子钙成像和来自症状前3xTg-AD和非转基因(NonTg)小鼠海马组织的蛋白质生物化学方法,我们发现阻断NO合成会导致3xTg-AD小鼠中通过突触前机制介导的突触抑制明显增强。此外,阻断NO会减少由增强的RyR钙释放介导的突触诱发的树突钙释放增强。这伴随着AD小鼠中nNOS水平的升高,并且在用慢性丹曲林治疗使RyR诱发的钙释放正常化后这种升高会逆转。因此,在AD早期阶段,NO的募集起到了代偿作用以增强突触传递和可塑性。然而,随着疾病进展,NO在神经保护和神经退行性变中的双重作用可能会转变为适应不良的功能。